Fig. 3: Repressive epigenetic signatures are associated with the HLA-I genes in cell lines with low HLA-I expression.
From: Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
HLA-I protein and gene expression was measured in four prostate cancer cell lines (LNCaP, 22rv1, PC3, and LAPC4) and a normal prostate epithelial cell line, RWPE1. a Western blot analysis of HLA-I expression in whole-cell lysates with alpha-tubulin as a loading control. b Flow cytometry analysis of extracellular HLA-I expression. c Gene expression of HLA-A, HLA-B, and HLA-C measured by qPCR relative to the housekeeping gene RPLP0 (P0) (n = 3). d Heat map showing DNA methylation levels in LNCaP, 22rv1, PC3, LAPC4, and RWPE1 in four regions of the HLA-I (n = 3). e Primer locations for DNA methylation and histone modification analyses. f Percent input of RWPE1 methylation and averaged methylation percent input in prostate cancer (PCa) cell lines (n = 3). g, h ChIP with antibodies targeting H3K27ac (n = 3) (g) and H3K27me3 (h) in LNCaP, 22rv1, PC3, and LAPC4 compared to RWPE1. i Correlation matrix of HLA-I gene and protein expression, DNA methylation levels, and histone modifications in LNCaP, 22rv1, PC3, LAPC4, and RWPE1. Error bars represent SEM.
